news
Topical valsartan found to be effective in accelerating chronic wound healing
A topical gel made from a class of common blood pressure medications has been found to accelerate the healing process of chronic skin wounds...
List view / Grid view
Entresto (sacubitril/valsartan)
news
Heart failure market worth $16 billion by 2026 as Novartis’ drug triggers growth
The heart failure space across the seven key markets of the US, France, Germany, Italy, Spain, the UK and Japan is set to grow from $3.7 billion in 2016 to around $16.1 billion by 2026, representing an impressive compound annual growth rate of 15.7%, according to research and consulting firm…
news
Heart failure treatment market to rise to $11.8 billion
4 May 2016 | By Victoria White, Digital Content Producer
The heart failure treatment market is set to rise from around $3.2 billion in 2015 to $11.8 billion by 2025, according to research and consulting firm GlobalData.
news
NICE recommends heart failure drug Entresto
27 April 2016 | By Victoria White, Digital Content Producer
The National Institute for Health and Care Excellence (NICE) has recommended Novartis’ Entresto (sacubitril valsartan) for some people with heart failure.
news
NICE recommends Novartis’ heart failure drug, Entresto
21 March 2016 | By Victoria White
The UK’s National Institute for Health and Care Excellence (NICE) has recommended Novartis’ heart failure drug, Entresto (sacubitrial/valsartan).
news
SMC accepts three medicines for use in NHS Scotland; rejects two
7 March 2016 | By Victoria White
The Scottish Medicines Consortium (SMC) has accepted three new medicines for routine use in NHS Scotland.
news
EC grants marketing authorisation to Entresto
25 November 2015 | By Victoria White
The European Commission has granted marketing authorisation to Novartis’ Entresto (sacubitril/valsartan) for the treatment of adult patients with symptomatic chronic heart failure with reduced ejection fraction (HFrEF).
news
CHMP recommends heart failure drug Entresto
25 September 2015 | By Victoria White
The CHMP has adopted a positive opinion for Novartis’ Entresto (sacubitril/valsartan), marking an important milestone towards the drug becoming available in the EU.
news
FDA approves heart failure treatment Entresto
8 July 2015 | By Victoria White
The US Food and Drug Administration (FDA) has approved Novartis' Entresto (sacubitril/valsartan) tablets for the treatment of heart failure with reduced ejection fraction.
